Atherosclerosis Clinical Trial
Official title:
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation
Ticagrelor and clopidogrel are FDA-approved drugs for inhibition of platelet hyper-reactivity in certain clinical situations. The platelet inhibition and patient outcomes (PLATO) trial showed that in patients with acute coronary syndromes, ticagrelor significantly reduced the primary endpoint (cardiovascular death, myocardial infarction or stroke), all-cause mortality and cardiovascular mortality compared to clopidogrel. It has been suggested that in addition to its anti-platelet effects, ticagrelor has additional unique effects, including anti-inflammatory effects that are not shared by clopidogrel. In the present study the investigators will assess whether ticagrelor, as compared to clopidogrel, increases serum levels of 15-epi-lipoxin A4, a potent endogenous anti-inflammatory mediator.
Clopidogrel, ticagrelor and prasugrel are routinely used for platelet inhibition in addition
to aspirin in patients after acute coronary syndromes. The platelet inhibition and patient
outcomes (PLATO) trial showed that in patients with acute coronary syndromes, ticagrelor
significantly reduced the primary endpoint (cardiovascular death, myocardial infarction or
stroke), all-cause mortality and cardiovascular mortality compared to clopidogrel. On the
other hand, when compared with clopidogrel in patients with acute coronary syndromes with
scheduled percutaneous coronary intervention, prasugrel therapy did not affect overall
mortality despite the fact that it was associated with significantly reduced rates of
ischemic events, including stent thrombosis, but with an increased risk of major bleeding,
including fatal bleeding. This may suggest that ticagrelor possesses additional (pleiotropic)
effects besides platelet inhibition.
The investigators have recently shown that pioglitazone increases 15-epi-lipoxin A4 blood
levels in patients. The investigators have recently found that in the rat, ticagrelor
increases tissue levels of 15-epi-lipoxin A4 in the heart, aorta and kidney.
It is plausible that some of the favorable effects of ticagrelor seen in the clinical studies
are mediated via the anti-inflammatory effects of 15-epi-lipoxin A4.
15-epi-lipoxin A4 is a potent anti-inflammatory and inflammation-resolving mediator derived
from arachidonic acid. Several studies have suggested that ticagrelor has anti-inflammatory
properties in various animal models. In the present study the investigators will assess if
ticagrelor increases blood 15-epi-lipoxin A4 levels at doses used in patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
| Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
| Completed |
NCT05906797 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.
|
N/A | |
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
| Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
| Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
| Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
| Recruiting |
NCT06230406 -
T-Mem GEne in Atherosclerosis
|
||
| Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
| Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
| Recruiting |
NCT02894931 -
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity
|
N/A | |
| Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
| Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
| Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
| Completed |
NCT02224339 -
New Technologies to Determine Carotid Plaque Vulnerability
|
||
| Completed |
NCT02268513 -
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
|
||
| Completed |
NCT03393377 -
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
|
N/A | |
| Not yet recruiting |
NCT01923012 -
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
|
Phase 2 | |
| Completed |
NCT02377310 -
Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography
|
N/A |